Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Asthma affects approximately 262 million people globally, with the number of asthma incidents having increased by around 15% ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Boehringer Ingelheim had previously explored Ofev as a treatment for ... this is also a very important and valuable ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

While at Boehringer Ingelheim, Dr. Mahaney’s teams were responsible for delivering drug candidates to the company’s global clinical portfolio, including several investigational assets in oncology, ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...